AUS
NZ
UK
CA
USA
IND
Croda International (LSE:CRDA), a chemicals company renowned for its high-quality products used in various industries, has seen its share price decline by 62% from its 2021 highs. The latest trading update initially painted a bleak picture, causing concern among investors. The company operates in sectors such as crop protection, beauty products, and life sciences, with the latter being a crucial part of its business.
Declining Sales in Life Sciences
A significant area of concern has been the performance of Croda's life sciences division. Sales in this segment dropped by 17.7% in the first half of 2024 compared to the last six months of 2023. This decline is partly attributed to a slowdown in lipid sales for COVID-19 vaccines, which accounted for £48 million at the end of last year. Excluding these sales, the drop is still 2%, suggesting that a return to previous levels may not be on the horizon.
This downturn in the life sciences segment is expected to impact the company's overall profitability for the year. Despite other divisions experiencing growth, operating income is projected to fall short of management's earlier expectations. This shortfall has contributed to the decline in the company's stock price.
Signs of Growth and Resilience
Despite the challenges, Croda International is not without its strengths. The company reported £881 million in revenues during the first half of 2023, which fell to £816 million in the first half of 2024, representing a 7% decline. However, this was largely due to a weak first quarter in 2024.
Encouragingly, Croda's sales have shown signs of recovery. In the last three months, the company generated £407.4 million in revenues, a 0.8% increase compared to the £404.2 million recorded in the second quarter of 2023.
